2009 Cancer in Washington

Annual Report of the
Washington State Cancer Registry

January 2012

For more information
regarding this report contact:

Washington State Cancer Registry
111 Israel Road SE, Third Floor
PO Box 47855
Olympia, WA  98504-7855

Phone:   360-236-3624, 1-888-302-2227
Fax:     360-586-2714
Website: https://fortress.wa.gov/doh/wscr

Mary Selecky
Secretary of Health
Prepared by:
Mahesh Keitheri Cheteri, PhD, Epidemiologist
Washington State Cancer Registry
Catherine O’Connor, Information Technology Specialist
Epidemiology, Health Statistics and Public Health Laboratories, Informatics Office
Juliet Van Eenwyk, PhD, Scientific Advisor to WSCR
Non-Infectious Conditions Epidemiology
Kathryn Golub, CTR, Surveillance/Operations Consultant
Washington State Cancer Registry

Acknowledgments:
Sue Grinnell, Director
Healthy Communities Office
Washington State Department of Health
Riley Peters, PhD, Manager
Surveillance and Evaluation
Washington State Department of Health
David Harrelson, Program Manager
Washington State Cancer Registry
Washington State Department of Health
Center for Health Statistics, Data Quality and Statistical Services
Washington State Department of Health
National Program of Cancer Registries
Centers for Disease Control and Prevention
Cancer Surveillance System
Fred Hutchinson Cancer Research Center
Washington CARES About Cancer Partnership and Committees
(Advisory to the State Cancer Registry)

Special acknowledgments:
The wide variety of health care facilities who report cancer data in Washington, their medical staffs, medical records personnel and especially cancer registrars, whose participation and cooperation help to make the Washington State Cancer Registry a tool in cancer control and prevention.

This work was funded in part by Centers for Disease Control and Prevention Cooperative Agreement # 5U58DP000793.

Data from the Cancer Surveillance System of Western Washington of the Fred Hutchinson Cancer Research Center are funded, in part, by Contract No. 1-CN-67009 from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute with additional support from the Fred Hutchinson Cancer Research Center and the Washington State Department of Health/Cancer Registry.
Contents

Preface 1
Introduction 1

Washington State Cancer Registry 1
  Background
  Data Collection
  Report Contents

Tables, Charts and Graphs 3
  Data Definitions and Sources
  Incidence and Mortality Summary
  Stage at Diagnosis
  Incidence and Mortality Rate Trends
  Incidence and Mortality Rates by County

References 6

Cancer by Site
  Percent Distribution of Cancer
  All Sites Combined
  Anus, Anal Canal and Anorectum
  Bladder
  Brain and Other Nervous System
  Breast (Female)
  Cervix (Uterine)
  Colorectal
  Endometrium
  Esophagus
  Hodgkin Lymphoma
  Kidney and Renal Pelvis
  Larynx
  Leukemia
  Liver and Intrahepatic Bile Duct
  Lung and Bronchus
  Melanoma of the Skin
  Myeloma
  Non-Hodgkin Lymphoma
  Oral Cavity and Pharynx
  Ovary
  Pancreas
  Prostate
  Soft Tissue Including Heart
Appendices

Appendix A: Technical Notes
Appendix B: Sources of Additional Information
Preface

This annual report of the Washington State Cancer Registry (WSCR) presents cancer data for Washington State with focus on cancer incidence data collected by WSCR. This information is presented to assist health care providers, public health officials, voluntary organizations, and concerned citizens in their efforts to prevent and control cancer in Washington.

This report no longer provides detailed information on the five most common cancer sites (breast, prostate, lung, melanoma, and colorectal) in Washington. The Health of Washington State (http://www.doh.wa.gov/hws/) provides information on female breast, lung, colorectal cancers and melanoma of the skin in Washington. The Washington State Comprehensive Cancer Control Plan (http://www.doh.wa.gov/Portals/1/Documents/Pubs/342-NonDOH-ComprehensiveCancerControlPlan.pdf) provides information on these cancer sites, as well as on prostate cancer from the perspective of the Washington CARES About Cancer Partnership.

Introduction

Cancer is a heterogeneous group of diseases characterized by uncontrolled growth and spread of abnormal cells. In 2009, there were 37,088 new cases of cancer diagnosed in Washington. The various forms of cancer were responsible for 11,903 deaths among Washington residents in 2009, comprising approximately twenty-five percent of all deaths. In 2009, cancer (all types combined) was the most common cause of death among adults aged 45 to 84 years and the leading cause of death across all age groups. Based on national data, some form of cancer will likely strike about 4 of 10 Washingtonians in their lifetime.1

Illness and death due to cancer are increasingly preventable through two types of strategies. Primary prevention strategies aim to reduce, usually through lifestyle change, the likelihood that a healthy individual will develop cancer. Secondary prevention is accomplished by screening asymptomatic people to diagnose cancers at an early and more readily treatable stage.

This report summarizes information on new cases of cancer (incidence) and deaths due to cancer (mortality) for Washington state residents and, for comparative purposes, the United States as a whole. The report provides information on cancer of all types combined and the 26 most frequently diagnosed cancers, which includes anus, anal canal and anorectum as a new cancer site that was added in 2008. This information can be used at the state and county levels to identify the burden of morbidity and mortality associated with each type of cancer. Combined with information on cancer prevention, early detection, and treatment, this information is useful for program planning and policy development aimed at reducing the burden of cancer.

Washington State Cancer Registry

Background

RCW 70.54.230 made cancer a reportable condition in Washington in 1990 and mandated the Department of Health to establish a statewide cancer registry program. Under this mandate, the Department established the Washington State Cancer Registry (WSCR) in 1991 with data collection starting January 1, 1992. The registry is dedicated
to fulfilling the legislative intent "...to establish a system to accurately monitor the incidence of cancer in the State of Washington for the purposes of understanding, controlling, and reducing the occurrence of cancer in this state." Since 1994, funding for WSCR has been provided, in part, through the Centers for Disease Control and Prevention’s National Program of Cancer Registries under Public Law 102-515. This program was authorized to establish standards for data collection (completeness, quality, and timeliness of reporting), and provide information for cancer prevention and control programs at the local, state, and national levels.

The North American Association of Central Cancer Registries (NAACCR) began certifying central cancer registries in 1997 as a means of recognizing achievements in case completeness, timeliness of reporting, and quality of data. WSCR has been recognized with NAACCR certification each year since 1997.

Data Collection

The cancer reporting rules (246-102 WAC) currently define reportable cancers as "any malignant neoplasm, with the exception of basal and squamous cell carcinoma of the skin." Also, specifically included are: 1) basal and squamous cell carcinoma of the external genital organs (vulva, labia, clitoris, prepuce, penis, anus, scrotum); 2) malignant and non-malignant intracranial and central nervous system tumors; 3) cancer in situ, except cancer in situ of the uterine cervix; and 4) certain hematopoietic conditions that have been recognized as potentially transforming into a malignancy. The legally required (Public Law 102-515, RCW 70.54.230, 246-102 WAC) data for cancer reporting includes patient demographics (age, sex and initial treatment) and medical information (type of cancer and date and stage at diagnosis) for all newly diagnosed cancers. Copies of Washington's cancer reporting legislation and regulations are available at http://apps.leg.wa.gov/rcw/ and http://apps.leg.wa.gov/wac/.

Cancer cases are collected through a variety of methods. Health care facilities, such as hospitals, independent laboratories, radiation/oncology treatment centers, ambulatory surgery centers, and health care providers are responsible for reporting cases to WSCR directly or indirectly. Washington State has agreements with other states to receive information on Washington residents who are diagnosed or treated in other states. The majority of Washington’s out-of-state cases are reported by Oregon and Idaho, followed by Texas and Arizona. WSCR is responsible for merging the data from multiple reporting sources conducting quality assurance in accordance with national standards, and disseminating de-identified cancer information to assist with cancer prevention and control efforts statewide and nationally.

Report Contents

This report includes a chapter summarizing the incidence and mortality for all cancers combined and for the 26 cancer sites most frequently diagnosed in Washington residents. In addition to the chapters for each site, there are introductory charts showing the relative frequency of the leading causes of cancer incidence and mortality. Appendices include technical notes and sources of information on the epidemiology and prevention of cancer.

The report focuses on cases of cancer newly diagnosed between January 1, 2009 and December 31, 2009 and reported to WSCR as of December 2011. For some sections, other years of cancer incidence data are used, as well. Cancer incidence information is for residents of the entire state and includes new cases of cancer among Washington
residents diagnosed in other states. Mortality statistics focus on deaths among Washington residents that occurred in 2009 where the underlying cause of death was cancer. The cancer may have been diagnosed before 2009. As with incidence, some sections use mortality data from additional years and mortality data include Washington residents who die out-of-state.

The following material briefly describes the tables, graphs and charts presented in the chapters for each of the 26 cancer sites. It includes short discussions of the statistical methods used to produce each table, graph or chart, and special considerations for interpreting the data.

**Tables, Charts and Graphs**

**Data Definitions and Sources**

The Washington State Cancer Registry provides the number of new cases (incidence) of cancer identified as described above. Based on estimates of the expected number of cancer cases, the registry includes more than 95 percent of cases. Beginning in 2001, each cancer was coded to an International Classification of Diseases Oncology Third Edition (ICD-O-3) code. Data from earlier years was converted to the ICD-O-3 code. The transition from ICD-O-2 to ICD-O-3 recognized and addressed advancements in diagnosing cancers, allowing pathologists to provide detailed information previously unavailable for certain cancers. The most significant of these changes was in the coding for lymphoma and leukemia. The data definition provides the ICD-O-3 codes used in each section.

The Washington State Department of Health, Center for Health Statistics provides information from death certificates on the number and causes of death. According to the National Center for Health Statistics, more than 99 percent of all deaths occurring in the United States are registered in the death certificate system. Accuracy of reporting specific causes of death varies since classification of disease conditions is a medical-legal opinion subject to the best information available to the physician, medical examiner, or coroner certifying the cause of death. WSCR obtained the number of cancer deaths from the Vital Registration System Annual Statistical Files, Washington State Deaths 1980–2009 issued October 2010.

From 1980–1998, the underlying cause of death was coded using the International Classification of Diseases, 9th Revision (ICD-9) coding system. Consistent with national requirements, the Department of Health began using the International Classification of Diseases, 10th Revision (ICD-10) beginning with deaths occurring in 1999. While the change from the ICD-9 to the ICD-10 resulted in substantive changes in rates for some causes of death, the effect of the coding change is small for cancer. Information on the comparability of ICD-9 and ICD-10 codes is available from the National Center for Health Statistics ([http://www.cdc.gov/nchs/datawh/nchsdefs/comparabilityratio.htm](http://www.cdc.gov/nchs/datawh/nchsdefs/comparabilityratio.htm)).

The data definition provides the ICD-10 codes used in each section. We have used definitions that are consistent with those used by the national Surveillance, Epidemiology and End Results (SEER) program. For some types of cancer, including colorectal, endometrial, leukemia, lung, myeloma and thyroid, the SEER coding differs from the National Center for Health Statistics coding. Before comparing information from different reports, one must be sure that the definitions are consistent.

Population data necessary for the calculation of rates are from the Washington State Office of Financial Management, December 2011. These include

**Incidence and Mortality Summary**

These tables provide the number of new cases of cancer and the number of cancer deaths for Washington State residents in 2009. Since the numbers of new cases and deaths depend, in part, on the size of the population, the numbers were converted to rates; i.e., the number of cases per 100,000 people, so that they may be compared among different regions or populations. For diseases, such as cancer, where incidence varies with age, the rates are age-adjusted to minimize the effect of different age distributions when comparing two geographic regions or populations.

Following national standards, we have age-adjusted rates to the 2000 U.S. standard population. **When making comparisons, one must be careful to compare age-adjusted rates that are adjusted to the same standard population and are calculated in the same manner.** Following the National Cancer Institute’s standard method, WSCR has used 19 age groups to age-adjust. This is different from the standard 11 age groups used by the National Center for Health Statistics. For this reason, the rates in this report may differ slightly from those published in other state or national reports. **Appendix A** provides detail on the age-adjustment method.

The final row of the incidence tables provides age-adjusted incidence rates from the 17 National Cancer Institute’s SEER regions. These rates are from SEER*Stat version 7.0.5 client-server mode public use file, April 2011. The final row of the mortality tables provides age-adjusted mortality rates for the United States. These rates are available for the total U.S. population through SEER*Stat version 7.0.5 client-server mode public use file. SEER obtains these data from the National Center for Health Statistics. The SEER programs do not include data for 2009. Since cancer incidence and mortality rates do not change rapidly, 2008 national data has been provided for comparison.

**Stage at Diagnosis**

Stage at diagnosis refers to how far a cancer has spread from its site of origin when it is diagnosed. The stages, in order of increasing spread, are in situ, local, regional and distant. Cancers staged as local, regional, distant, or unstaged are referred to as invasive. The reader should note that many publications of the National Cancer Institute and the Centers for Disease Control and Prevention report rates of invasive cancer only. Thus, caution must be exercised when comparing incidence rates contained in different reports.

The WSCR data contain the stage of disease at diagnosis coded according to the national guidelines. This report uses the derived SEER summary stage 2000 staging information, that is calculated using the collaborative staging algorithm. The five different stage groups (in situ, localized, regional, distant and unstaged) are defined below.

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>In Situ</td>
<td>A tumor that fulfills all microscopic criteria for malignancy but does not invade or penetrate surrounding tissue.</td>
</tr>
<tr>
<td>Localized</td>
<td>A tumor that is invasive but remains restricted to the organ of origin.</td>
</tr>
<tr>
<td>Regional</td>
<td>A tumor that has spread by direct extension to immediately adjacent organs or tissues and/or metastasized (spread through the blood stream) to regional lymph nodes, but</td>
</tr>
</tbody>
</table>
appears to have spread no further.

Distant A tumor that has spread by direct extension beyond the immediately adjacent organs or tissues and/or metastasized to distant lymph nodes or other distant tissues.

Unstaged Insufficient information available to determine the stage of disease at diagnosis.

WSCR has provided the frequency distribution of cases according to their stage at diagnosis.

For most cancers, diagnosis at an early stage (in situ or local) results in improved survival. One standard measure of survival is the five-year survival rate that estimates the proportion of individuals with a given cancer who are living five years after diagnosis. We have not developed five-year survival rates for Washington State residents. However, WSCR has provided the SEER five-year survival rates for each cancer. These statistics were obtained from SEER*Stat version 7.0.5 client server mode public-use file, April 2011. This data file provides survival rates by stage of disease at diagnosis. The national five-year relative survival rates are calculated for cancer cases diagnosed between 2003 and 2007, based on follow-up of patients through 2008. The National Cancer Institute defines the relative five-year survival rate as the likelihood that a patient will not die from causes associated with their cancer within five years. The SEER*Stat program calculates this rate using a procedure described by Ederer, Axtell, and Cutler whereby the observed survival rate is adjusted for expected mortality. It is always larger than the observed survival rate.

Incidence and Mortality Rate Trends

These graphs provide incidence and mortality rates from 1992–2009 for Washington residents per 100,000 population, age-adjusted to the U.S. 2000 standard population. (See Incidence and Mortality Summary for a discussion of age-adjusted rates.) These graphs show changes in rates over time for all Washington residents and for males and females separately. Joinpoint software, version 3.5.2, developed by the National Cancer Institute was used to test for changes over time. This software calculates the annual percent change (APC). Following the method described by Ries et al. to interpret findings from the Joinpoint analyses, we describe rates as level over time when the APC is not statistically significantly different from zero (p > 0.05). For statistically significant trends (p < 0.05), the increase or decrease is described as slight if the APC is less than 1 percent, steady if the APC is between 1 to 3.9 percent and sharp if the APC is greater than or equal to 4 percent. As described in Data Definitions and Sources above, there were coding changes for new cancer cases in 2001 and for causes of death in 1999. For new cancer cases, the coding changes did not result in discontinuities from earlier data for the 26 cancer sites covered in this report. The same is true for death from cancer. Therefore, the 1992–2009 data were treated as a continuous series.

Incidence and Mortality Rates by County

WSCR has presented the average annual age-adjusted cancer incidence and mortality rates for Washington residents per 100,000 population by county. (See Incidence and Mortality Summary for a discussion of age-adjusted rates.) Because of the small size of many counties and the relative rarity of some types of cancer, the incidence and
mortality rates based on one year of data are not stable; i.e., there is some random fluctuation in rates from year to year. Therefore, for county rates, WSCR combined three years of data (2007-2009) to compute average annual age-adjusted rates for the three-year period.

The state rates and 95 percent confidence intervals are included for comparison purposes. While the incidence and death statistics in this report are not subject to sampling error, they may be affected by random variation. The confidence interval is used to describe the range of that variation.

When the confidence interval for the rate of interest does not overlap with the confidence interval for the comparison rate, the two rates are statistically significantly different; i.e., the difference between the two rates is more than that expected by random variation or chance. However, if WSCR is making many comparisons statistically significant differences may still be found just by chance. In fact, with a 95 percent confidence interval, it is expected that 5 percent of the comparisons will be statistically significant by chance. If, for example, rates for 26 cancer sites in 39 counties to state rates are compared, 1014 comparisons are made (26 times 39). Just by chance alone, statistically significant differences are expected for about 50 (5 percent of 1014) of those comparisons.

If the confidence interval for the rate of interest; e.g., a confidence interval around a county rate, includes the rate for the comparison area; e.g., the state rate, the rates are not statistically significantly different. When confidence intervals for the rate of interest and the comparison rate overlap, the interval for the rate of interest does not include the rate for the comparison area, the differences might or might not be statistically significant and formal statistical testing is needed to determine statistical significance.

Even with a three-year average, rates may fluctuate widely when there are a small number of cases. Therefore, WSCR omits the rate and confidence intervals when there are nine or fewer cases for the three-year period. Details of our methods for calculating confidence intervals are in Appendix A.

References


Appendices

Appendix A:  Technical Notes

Appendix B:  Sources of Additional Information
Appendix A: Technical Notes

Age-Adjustment

Age-adjusted incidence rates were developed using the direct method. They were standardized to the age distributions of the United States 2000 standard population. Following the age-adjustment procedures used by the National Cancer Institute we used 19 age groups in calculating age-adjusted rates. The age distribution of the 2000 US standard population is shown below.

**US Standard Population Proportions**

<table>
<thead>
<tr>
<th>age group</th>
<th>proportion</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1</td>
<td>0.013818</td>
</tr>
<tr>
<td>1 - 4</td>
<td>0.055317</td>
</tr>
<tr>
<td>5 - 9</td>
<td>0.072532</td>
</tr>
<tr>
<td>10 - 14</td>
<td>0.073032</td>
</tr>
<tr>
<td>15 - 19</td>
<td>0.072168</td>
</tr>
<tr>
<td>20 - 24</td>
<td>0.066478</td>
</tr>
<tr>
<td>25 - 29</td>
<td>0.064530</td>
</tr>
<tr>
<td>30 - 34</td>
<td>0.071044</td>
</tr>
<tr>
<td>35 - 39</td>
<td>0.080762</td>
</tr>
<tr>
<td>40 - 44</td>
<td>0.081851</td>
</tr>
<tr>
<td>45 - 49</td>
<td>0.072118</td>
</tr>
<tr>
<td>50 - 54</td>
<td>0.062716</td>
</tr>
<tr>
<td>55 - 59</td>
<td>0.048454</td>
</tr>
<tr>
<td>60 - 64</td>
<td>0.038793</td>
</tr>
<tr>
<td>65 - 69</td>
<td>0.034264</td>
</tr>
<tr>
<td>70 - 74</td>
<td>0.031773</td>
</tr>
<tr>
<td>75 - 79</td>
<td>0.027000</td>
</tr>
<tr>
<td>80 - 84</td>
<td>0.017842</td>
</tr>
<tr>
<td>85+</td>
<td>0.015508</td>
</tr>
</tbody>
</table>

**Direct method of age adjustment**

Multiply the age-specific rates in the target population by the age distribution of the standard population.

\[
\hat{R} = \sum_{i=1}^{m} s_i \left( \frac{d_i}{P_i} \right) = \sum_{i=1}^{m} w_i d_i
\]

Where \( m \) is the number of age groups, \( d_i \) is the number of events in age group \( i \), \( P_i \) is the population in age group \( i \), and \( s_i \) is the proportion of the standard population in age group \( i \). This is a weighted sum of Poisson random variables, with the weights being \( \left( \frac{s_i}{P_i} \right) \).
**Confidence Intervals**

Confidence intervals for the age-adjusted rates were calculated with a method based on the gamma distribution (Fay and Feuer, 1997). This method produces valid confidence intervals even when the number of cases is very small. When the number of cases is large the confidence intervals produced with the gamma method are equivalent to those produced with the more traditional methods, as described by Chiang (1961) and Brillinger (1986). The formulas for computing the confidence intervals are given below. Although the derivation of this method is based on the gamma distribution, the relationship between the gamma and Chi-squared distributions allows the formulas to be expressed in terms of quantiles of the Chi-squared distribution, which can be more convenient for computation.

\[
\text{Lower Limit} = \frac{v}{2y} \left( \chi^2_2 \right)_{\frac{\alpha}{2}}^{\frac{1}{2}}
\]

\[
\text{Upper Limit} = \frac{v + w_M^2}{2(y + w_M)} \left( \chi^2_2 \right)_{\frac{1}{2} \left( y + w_M \right)^2}^{\frac{1}{y + w_M^2}} \left( 1 - \frac{\alpha}{2} \right)
\]

where \( y \) is the age-adjusted rate, \( v \) is the variance as calculated as shown below, \( w_M \) is the maximum of the weights \( s_i P_i \), \( 1 - \alpha \) is the confidence level desired (e.g., for 95% confidence intervals, \( \alpha = 0.05 \)), and \( \left( \chi^2_2 \right)^{-1} \) is the inverse of the \( \chi^2 \) distribution with \( x \) degrees of freedom.

\[
v = \sum_{i=1}^{m} d_i (s_i / P_i)^2
\]

**References**


Appendix B: Sources of Additional Information

For more information on cancer, risk factors or prevention strategies please refer to the following resources:

1-800-4-CANCER: A cancer information service of the National Cancer Institute

American Cancer Society, Western-Pacific Division: 1-800-729-1151 ext. 3307
American Cancer Society, Cancer Facts and Figures

Centers for Disease Control and Prevention website: http://www.cdc.gov/cancer/index.htm


American College of Surgeons National Cancer Database website: http://www.facs.org
